May 14, 2019 / 12:32 PM / 2 months ago

BRIEF-Cincor Pharma Closes $50 Mln Series A Financing

May 14 (Reuters) - CinCor Pharma, Inc:

* CINCOR PHARMA IN-LICENSES ALDOSTERONE SYNTHASE INHIBITOR, CIN-107, AND CLOSES $50 MILLION SERIES A FINANCING

* CINCOR PHARMA - SIGNED AN AGREEMENT WITH ROCHE TO ACQUIRE EXCLUSIVE GLOBAL RIGHTS TO A NOVEL ALDOSTERONE SYNTHASE INHIBITOR COMPOUND, CIN-107

* CINCOR PHARMA - CIN-107 WILL BE DEVELOPED FOR TREATMENT RESISTANT HYPERTENSION AND PRIMARY ALDOSTERONISM

* CINCOR PHARMA - FINANCIAL TERMS OF LICENSING AGREEMENT WERE NOT DISCLOSED

* CINCOR PHARMA - IN CONJUNCTION WITH EXECUTION OF LICENSE AGREEMENT, CO COMPLETED A $50 MILLION SERIES A FINANCING LED BY SOFINNOVA INVESTMENTS

* CINCOR PHARMA - SOFINNOVA PARTNERS AND 5AM VENTURES ALSO PARTICIPATED IN $50 MILLION SERIES A FINANCING

* CINCOR PHARMA - IN CONJUNCTION WITH FINANCING, MAINA BHAMAN FROM SOFINNOVA PARTNERS AND DAVID ALLISON FROM 5AM VENTURES HAVE ALSO JOINED CO'S BOARD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below